Dr. Matthias Magoola, founder and managing director of Dei BioPharma, has been named among Africa's 100 Most Influential People for 2026. The recognition was announced in Kigali on September 25 by the Accra-based Business Executive Media Group. Magoola's work in biotechnology and pharmaceuticals was cited as a significant contribution to Africa's ability to produce its own medicines and vaccines. His visionary leadership and innovations were praised for their potential to drive economic development and healthcare transformation in Africa.
Dei BioPharma is currently developing a large drug and vaccine manufacturing plant in Mattuga, Wakiso district. Magoola has identified affordable cancer treatment, reduced dependence on imported vaccines, and training of African researchers as priorities. The company has filed over 100 patent applications with the United States Patent and Trademark Office, covering proposed treatments and vaccines for various diseases, including cancer, HIV/Aids, and malaria. These patent filings record claims to inventions, but further evidence and development are needed to prove their safety and effectiveness.
One of the patent filings describes an "Affordable Universal Fusion Vaccine for Foot and Mouth Disease Infections," which was accepted for publication in September. Magoola has presented this as a possible locally developed alternative to imports that could save government money. Another filing describes a guided mRNA approach intended to target mutated genes in cancer. The development of these products and their potential impact on patients will depend on further research and testing.
The selection process for Africa's 100 Most Influential People begins with research consultants and ends with a 12-member jury drawn from fields including politics, economics, culture, and diplomacy. The award recognizes perceived influence and achievement, separate from the scientific and regulatory tests a new medicine must pass. Magoola's recognition follows two earlier awards: a 2025 Ratna Pharma Award in India for vaccine research and a December 2024 International Molecular Biologist Award for work on mRNA-based drugs and vaccines.
At the ceremony, University of Rwanda vice-chancellor Prof Didas Muganga Kayihura urged African institutions to pursue innovation that strengthens their economies. Magoola credited President Yoweri Museveni's support for the work, saying, "Without his unwavering support, these milestones would not be possible." The recognition highlights the importance of government support for scientific research and innovation in Uganda.
For Uganda, the next measure of this recognition will be practical. It remains to be seen which products Dei BioPharma can manufacture now, which remain in research, and whether any resulting medicines will reach patients at prices they can afford. The development of local manufacturing capacity and the availability of affordable medicines will be key indicators of the impact of Magoola's work.
The award also raises questions about the potential for research and manufacturing in Uganda to reduce reliance on imported health products. If successful, Dei BioPharma's efforts could have significant implications for healthcare in Uganda and beyond. The company's progress will be closely watched by stakeholders in the healthcare sector.
Key points
- Dr. Matthias Magoola's recognition as one of Africa's 100 Most Influential People for 2026 highlights his contributions to biotechnology and pharmaceuticals in Africa.
- Dei BioPharma is developing a large drug and vaccine manufacturing plant in Mattuga, Wakiso district, with the goal of producing affordable medicines.
- The development of local manufacturing capacity and the availability of affordable medicines will be key indicators of the impact of Magoola's work.
